Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Leukemia
100%
Chromosomal Aberrations
100%
International Workshop
100%
Inpatient Treatment
100%
Therapy-related Myelodysplastic Syndrome (t-MDS)
100%
Blood or Marrow Transplantation
55%
Aberrations
33%
Primary Disease
33%
Alkylating Agents
22%
Radiotherapy
22%
Risk Factors
22%
Primary Diagnosis
22%
Recurring
11%
Doxorubicin
11%
Chemotherapy
11%
Acute Lymphoblastic Leukemia
11%
Current Therapies
11%
Median Survival
11%
Delayed Diagnosis
11%
5-year Survival
11%
Relative Risk
11%
Risk of Death
11%
Topoisomerase
11%
Cytarabine
11%
Methotrexate
11%
VP16
11%
Multivariate Analysis
11%
Past Exposure
11%
L-asparaginase
11%
Complex Karyotype
11%
Patient Relatives
11%
Daunorubicin
11%
Young Age
11%
Final Model
11%
11q23 Abnormality
11%
Mitoxantrone
11%
Prednisone
11%
Multivariable Model
11%
1-year Mortality
11%
Cytogenetic Abnormalities
11%
Short Latency
11%
Lomustine
11%
11q23 Translocation
11%
19p13.3
11%
4q21
11%
Relative Risk of Death
11%
16p13.1
11%
Del(7q)
11%
6q27
11%
Treatment Start
11%
Adverse Risk
11%
Medicine and Dentistry
Chromosome Aberration
100%
Acute Leukemia
100%
Myelodysplastic Syndrome
100%
Diseases
30%
Karyotype
20%
Alkylating Antineoplastic Agent
20%
Radiation Therapy
20%
Doxorubicin
10%
Acute Lymphoblastic Leukemia
10%
Methotrexate
10%
Cytarabine
10%
Liposomal Daunorubicin
10%
Vincristine
10%
Etoposide
10%
Mitoxantrone
10%
Lomustine
10%
Prednisone
10%
Topoisomerase
10%
Asparaginase
10%
Teniposide
10%
Chemotherapy
10%
Multivariate Analysis
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chromosome Aberration
100%
Acute Leukemia
100%
Myelodysplastic Syndrome
100%
Diseases
30%
Alkylating Agent
20%
Doxorubicin
10%
Acute Lymphoblastic Leukemia
10%
Cytarabine
10%
Methotrexate
10%
Chemotherapy Regimens
10%
DNA Topoisomerase
10%
Daunorubicin
10%
Vincristine
10%
Mitoxantrone
10%
Etoposide
10%
Prednisone
10%
Lomustine
10%
Asparaginase
10%
Teniposide
10%
Immunology and Microbiology
Karyotype
100%
Chromosome
100%
Prednisone
50%
Methotrexate
50%